Search the Newsreel

Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent

Sanofi's SNY most important medicine remains its immunology drug, Dupixent, which continues to be the company's primary growth engine. Dupixent sales represented roughly 42% of Sanofi's first-half 2026 revenues. Sanofimarkets Dupixent in partnership with Regeneron REGN. While sales are recorded by Sanofi, Regeneron records …

Why Is Sanofi (ENXTPA:SAN) Reshaping Its Business Around Vaccines And Mature Medicines?

Sanofi (ENXTPA:SAN) opened the Charles Best Building in Canada, described as the largest biomanufacturing investment in the country. The new Canadian site expands Sanofi's flu vaccine production capacity, with the goal of strengthening readiness for future influenza seasons. Sanofi agreed to transfer a portfolio …

Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine

Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss

Sanofi Opens New Flu Vaccine Facility in Toronto

Sanofi inaugurates new flu vaccine facility, Canada's largest biomanufacturing investment

The $925 million (CAD) expansion is adding end-to-end vaccine manufacturing capacity on Canadian soil Built in partnership with the Government of Canada, the Province of Ontario, and the City of Toronto to bolster the country's vaccine biomanufacturing capabilities and support Canada's national response to …

Sanofi-Aktie: Schöne Dividende – doch auch Kurschancen!

Sanofi (ENXTPA:SAN) Stock May Be Undervalued Despite Its Mature Medicines Deal

Sanofi has delivered mixed returns over recent years, and with the share price around €75.43, the real issue for you is whether that level is justified by the earnings power the group is producing today. Over the past 3 years, the stock has declined …

Cheplapharm to take over 20 medicines and three sites from Sanofi

Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities globally, from Sanofi. Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between …

Sanofi to Acquire 26.4% Stake in Cheplapharm

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Sanofi Winthrop Industrie Sanofi and Cheplapharmto create new strategic partnership in mature medicines Paris, September 14, 2026. Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a …

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

INmune Bio, Inc. Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today …

Sanofi: Information concerning the total number of voting rights and shares - August 2026

Sanofi Winthrop Industrie Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the …

Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot

Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™

Despite their risk of serious illness from COVID-19, nearly 70% of adults 65 and older remain unvaccinated, in part due to concerns about potential side effects The campaign serves up COVID-19 prevention education, including details about NUVAXOVID™ and its established tolerability MORRISTOWN, N.J. and …

RBC Initiates Sanofi at Sector Perform With EUR80 Price Target

Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®

Emmy Award-winning actress, entrepreneur and mom Keke Palmer partners with Sanofi to help educate families about protection against a serious respiratory syncytial virus (RSV) lung infection BEYFORTUS has been chosen by millions of parents to help protect their babies from serious RSV lung infection, …

Die Sanofi-Aktie haelt sich stabil, waehrend Dupixent das Wachstum traegt

Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?

Quick Read NVAX jumped 7% on unverified Matrix-M oncology speculation, even as the real story had already quietly resumed: high-teens royalties on Sanofi's Nuvaxovid global net sales restarted for 2026 and 2027. IBB gained just 0.2% while NVAX soared, and a $125 million Sanofi …

Regeneron Seen Weighing Expanded Sanofi Deal, RBC Says

Sanofi (ENXTPA:SAN) Permanently Halted Its Phase 3 Infant RSV Vaccine Trial

Sanofi (ENXTPA:SAN) has permanently halted its Phase 3 RSV vaccine trial in infants and toddlers following a serious adverse event involving an infant death. The death was later linked to an underlying health condition that should have excluded the child from the study, prompting …

Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?

For income investors, there's a solid stock that pays a handsome dividend and, due to a recent decline in its share price, is trading at a bargain-basement price. I'm talking about Sanofi (NASDAQ: SNY), the French multinational pharmaceutical that is focused on immunology, vaccines, …

Is Sanofi (ENXTPA:SAN) Reasonable After A 10% Three Year Slide?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Sanofi stock is coming off a mixed three year stretch, with the share price down about 10.5%, yet current valuation checks on earnings …

Die Sanofi-Aktie reagiert nach starken Quartalszahlen und neuer Prognose

Sanofi: Information concerning the total number of voting rights and shares - July 2026

Sanofi Winthrop Industrie Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the …

AimwellBio Publishes Investor Briefing on Acquired Trustr Intellectual Property Portfolio Valued at $10m Reinforcing Commitment to Transparency

Behavioral engagement technology carries documented institutional lineage spanning Oxford, the University of Vermont, Cornell, AMCP, and a Sanofi pilot program, as inventor Dr. Chris A. Jones joins AimwellBio's Board of Advisors and leads further expansion. MIAMI, FL / ACCESS Newswire / August 13, 2026 …

Big Tech Drives Up Credit Risk for Safe Firms With No AI Links

(Bloomberg) -- As a flood of debt sales by US tech companies ripples through the credit market, it seems to be triggering an inadvertent rise in risk metrics for some of the world's safest firms. Most Read from Bloomberg Walter Sells Lakers, Seeks More …

Die Sanofi-Aktie legt nach starken Q2-2026-Zahlen und erhöhter Prognose zu

[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach …

U.K. regulator reaffirms safety of childhood vaccination

[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the …

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Adagene Inc. Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular …

InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001

IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation …

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion …